| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Editorial board
|
|
Editorial board
|
page ii
|
| Editorial |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
The Renaissance clinician: Essential for the modern management of prostate cancer
This special issue of the European Journal of Cancer, focusing on the biology and management of prostate cancer, illustrates clearly the changing demands on the clinician treating this complex disease...
|
Derek Raghavan
|
Editorial
|
pages 823-824
|
|
|
Screening for prostate cancer
Abstract: Epidemiologically, prostate cancer is the most common cancer in the Western world after skin cancer. To date, it is still unknown whether screening for prostate cancer is justified, because ...
|
R. Postma,
F.H. Schröder
|
Full-length article
|
pages 825-833
|
|
|
Changing demography of prostate cancer in Asia
Abstract: There has been a recent trend in Asia towards increasing incidence of prostate cancer, with some low-risk regions, such as Japan and Singapore, reporting a more rapid increase than high-risk...
|
Hong Gee Sim,
Christopher W.S. Cheng
|
Full-length article
|
pages 834-845
|
|
|
Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate
Abstract: The prostate is a highly androgen-dependent tissue that in humans exhibits marked susceptibility to carcinogenesis. The malignant epithelium generated from this tissue ultimately loses depen...
|
David Danielpour
|
Full-length article
|
pages 846-857
|
|
|
Molecular markers of prostate cancer outcome
Abstract: Molecular markers have the potential to serve not only as prognostic factors but may be targets for new therapeutic strategies and predictors of response in a range of cancers. Prostate canc...
|
David I. Quinn,
Susan M. Henshall,
Robert L. Sutherland
|
Full-length article
|
pages 858-887
|
|
|
Surgical management of prostate cancer: Advances based on a rational approach to the data
Abstract: The management of localised prostate cancer has undergone important changes in the past two decades, with major improvements in surgical technique, a greater emphasis on structured assessmen...
|
Anoop M. Meraney,
Alexander Haese,
Jüri Palisaar,
Markus Graefen,
Thomas Steuber,
Hartwig Huland,
Eric A. Klein
et al.
|
Full-length article
|
pages 888-907
|
|
|
Technological advances in radiotherapy for the treatment of localised prostate cancer
Abstract: There is good evidence that radiation dose escalation in localised prostate cancer is associated with increased cell kill. The traditional two-dimensional (2D) technique of treatment plannin...
|
Stephen A. Mangar,
Robert A. Huddart,
Christopher C. Parker,
David P. Dearnaley,
Vincent S. Khoo,
Alan Horwich
et al.
|
Full-length article
|
pages 908-921
|
|
|
Quality of life in prostate cancer
Abstract: Little more than a decade ago, measurements of health-related quality of life (HRQOL) of prostate cancer patients began to enter the medical literature. Initially controversial and of little...
|
James A. Talcott,
Jack A. Clark
|
Full-length article
|
pages 922-931
|
|
|
Prostate cancer metastases to bone: Pathophysiology, pain management, and the promise of targeted therapy
Abstract: Bone metastases are a significant cause of pain and morbidity in prostate cancer, especially if they lead to complications such as pathological fractures and spinal cord compression. Palliat...
|
Jacek Pinski,
Tanya B. Dorff
|
Full-length article
|
pages 932-940
|
|
|
Clinical trials in metastatic prostate cancer – Has there been real progress in the past decade?
Abstract: Hormone refractory prostate cancer remains a challenge. While only palliative treatment strategies were available for the past several decades, many promising agents have been investigated o...
|
Manish S. Bhandari,
Daniel P. Petrylak,
Maha Hussain
|
Full-length article
|
pages 941-953
|
|
|
Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?
Abstract: In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus b...
|
John M. Strother,
Tomasz M. Beer,
Robert Dreicer
|
Full-length article
|
pages 954-964
|
